- Pimecrolimus: Indications, Side Effects, Warnings - Drugs. com
Easy-to-read patient leaflet for Pimecrolimus Includes indications, proper use, special instructions, precautions, and possible side effects
- Pimecrolimus (topical route) - Side effects dosage
Pimecrolimus is used to treat mild to moderate atopic dermatitis (eczema) in patients who have already been treated with other medicines that did not work well Pimecrolimus belongs to a class of medicines known as topical calcineurin inhibitors that decrease inflammation
- Pimecrolimus (Elidel) - Uses, Side Effects, and More - WebMD
Find patient medical information for Pimecrolimus (Elidel) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings
- Pimecrolimus - Wikipedia
Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema) It is available as a topical cream It was developed and formerly marketed by Novartis under the trade name Elidel
- Elidel (pimecrolimus): Uses, Side Effects, Alternatives More - GoodRx
Learn about pimecrolimus (Elidel) usage and dosing Read the latest news and reviews about the drug as well as potential side effects and popular alternatives
- Pimecrolimus - DermNet
What is pimecrolimus? Pimecrolimus is a topical steroid-free medication with immune-modulating and anti- inflammatory properties, used to treat atopic dermatitis It is classified as a calcineurin inhibitor and an ascomycin macrolactam derivative; ascomycin is produced by Streptomyces hygroscopicus
- Pimecrolimus Cream: Uses Side Effects - Cleveland Clinic
What is this medication? PIMECROLIMUS (pim e KROW li mus) reduces swelling, redness, itching, or rashes caused by skin conditions, such as eczema It works by slowing down an overactive immune system
- pimecrolimus (Elidel) Uses, Side Effects Dosage - MedicineNet
Pimecrolimus (Elidel) is a medication prescribed for the short-term treatment of mild to moderate atopic dermatitis in persons who are 2 years of age or older, and who cannot use or have failed to respond to other therapies
|